The content on this site is intended for healthcare professionals only
Prof Evangelos Terpos (University of Athens, Athens, Greece), Prof Heinz Ludwig (Wilhelmeninen Cancer Research Institute, Vienna, Austria), Prof Michele Cavo (Bologna University School of Medicine, Bologna, Italy) and Prof Meral Beksac (Ankara University Medical School, Ankara, Turkey) discuss the latest developments in the use of immunotherapy for relapsed or refractory multiple myeloma.
Prof Terpos starts the discussion by mentioning the real-world data for belantamab mafodotin treatment for patients with relapsed/refractory myeloma.
They then discuss the relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin.
The panel further talks about matching adjusted indirect comparison of ciltacabtagene autoleucel versus belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
They also discuss the phase 1 study of elranatamab (PF-06863135), a B-cell maturation antigen targeted CD3-engaging bispecifc antibody, for patients with relapsed or refractory multiple myeloma.
They conclude by discussing the efficacy of isatuximab, carfilzomib, lenalidomide, and dexamethasone (ISA-KRD) in front-line treatment of high-risk multiple myeloma and isatuximab (ISA) plus pomalidomide and low-dose dexamethasone versus PD in relapsed and refractory multiple myeloma.
| Belantamab Mafodotin treatment for patients with r/r myeloma: Real world data | |
| Characterisation of ocular adverse events in patients receiving belantamab mafadotin for ≥12 months | |
| Relationship between corneal exam findings, BCVA and ocular symptoms in patients with RRMM receiving belantamab mafodotin | |
| Matching adjusted indirect comparison of ciltacabtagene autoleucel versus belantamab mafodotin in patients with RRMM | |
| Elranatamab a BCMA targeted CD3-engaging bispecifc antibody, for patients with RRMM | |
| Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in patients with RRMM | |
| Updates from Icaria-MM study | |
This programme has been supported by an unrestricted educational grant from GSK.
30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma
SIOG 2024: Updates in haematology
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
